

CAMCEVI® (leuprolide) Medication Precertification Request

Page 1 of '

(All fields must be completed and legible for precertification review.)

Aetna Precertification Notification Phone: <u>1-866-752-7021</u> (TTY: <u>711</u>)

FAX: <u>1-888-267-3277</u>

For Medicare Advantage Part B: Please Use Medicare Request Form

Please indicate: ☐ Start of treatment: Start date ☐ Continuation of therapy, Date		/			
Precertification Requested By:	·			Fax:	
A. PATIENT INFORMATION					
First Name:	Last Name:		DOB:		
Address:	City:		State:	ZIP:	
Home Phone: Work Phone:		Phone:	Email:		
Patient Current Weight:lbs orkgs Pa		1	L		
B. INSURANCE INFORMATION	mone riolgnamilones	ororrio / morg			
Aetna Member ID #:	Does patient have other	er coverage?	∕es □ No		
Group #:					
Insured:	Insured:				
Medicare: ☐ Yes ☐ No If yes, provide ID #:	Mec	dicaid: 🗌 Yes 🗌 No	o If yes, provide ID #:		
C. PRESCRIBER INFORMATION					
First Name:	Last Name:		(Check One): M.D	. 🗌 D.O. 🗌 N.P. 🗌 P.A.	
Address:		City:	State:	ZIP:	
Phone: Fax:	St Lic #:	NPI #:	DEA #:	UPIN:	
Provider Email:	Office Contact Name:		Phone:	<u> </u>	
Specialty (Check one): Oncologist Other:			-		
D. DISPENSING PROVIDER/ADMINISTRATION IN					
Place of Administration:		Dispensing Provi	der/Pharmacy: Patient	Selected choice	
☐ Self-administered ☐ Physician's Office		Physician's Office Retail Pharmacy			
Outpatient Infusion Center Phone:		☐ Specialty Pharmacy ☐ Other			
Center Name:		Name:			
☐ Home Infusion Center Phone:		Address:			
Agency Name:			Fax		
Address:			PIN:		
Address:		· · · · · ·	· "`	•	
E. PRODUCT INFORMATION		F			
Request is for: CAMCEVI (leuprolide) Dose:					
F. DIAGNOSIS INFORMATION - Please indicate pri					
Primary ICD Code: Other					
For All Requests (clinical documentation required):	ormation must be completed	in its <u>entirety</u> for all p	recertification requests.		
Yes No Does the patient have a diagnosis of pr	ostate cancer?				
For Initiation Requests (clinical documentation requi					
Yes No Has the patient had an ineffective response		erance to Eligard?			
For Continuation Requests (clinical documentation r	•	o o			
☐ Yes ☐ No Has the patient experienced clinical ber		sted drug (e.g., serum t	estosterone less than 50 ι	ng/dL)?	
☐ Yes ☐ No Is there evidence of unacceptable toxic	ty while on the current regime	en?			
H. ACKNOWLEDGEMENT					
Request Completed By (Signature Required):			Da	te: / /	
Any person who knowingly files a request for author any insurance company by providing materially false insurance act, which is a crime and subjects such pe	e information or conceals ma	aterial information for			

The plan may request additional information or clarification, if needed, to evaluate requests.